The DOI matches its Crossref record.
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Abstract
PURPOSE: High cumulative epipodophyllotoxin dosages are reported to be associated with an elevated risk for secondary acute myeloid leukemia (s-AML). This study examined the risk of s-AML following cumulative etoposide doses greater than 2 g/m2 in patients with metastatic germ cell tumors (GCT). PATIENTS AND METHODS: The incidence of s-AML was retrospectively assessed in patients treated within clinical trials between January 1986 and February 1996 at four university centers. All patients received high-dose chemotherapy (HDCT) plus autologous stem-cell support for metastatic GCT, including high cumulative etoposide doses (> 2 g/m2). Minimum patient follow-up was 12 months. Standardized morbidity ratio (SMR) was calculated to estimate the risk associated with high cumulative etoposide doses, as compared with the general population. RESULTS: A total of 302 patients with a median age of 29 years (range, 15 to 55) received a median cumulative etoposide dose of 5 g/m2 (range, 2.4 to 14 g/m2). Four cases of s-AML were observed, which resulted in a cumulative incidence of 1.3% (95% confidence interval [CI], 0.38% to 3.59%) at 52 months of median follow-up (range, 12 to 198). Two cases of secondary myelodysplasia (s-MDS) developed in patients with primary mediastinal GCT. Based on the observed four cases of AML, which are most likely etoposide-related, the risk for developing s-AML (SMR, 160 [95% CI, 43.7 to 411.2]) is significantly increased in comparison to the age-matched general population. CONCLUSION: Due to the low incidence of AML in the general population, the significantly elevated risk for developing s-AML affects only 1.3% of all patients who receive etoposide doses greater than 2 g/m2. HDCT, including etoposide doses greater than 2 g/m2, is associated with an acceptably low incidence of s-AML in patients with advanced GCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Self-citationMedical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Platet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.001 · Cited by 367
Baker, K. S., DeFor, T. E., Burns, L. J., Ramsay, N. K. C., Neglia, J. P., & Robison, L. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.108 · Cited by 317
Guidelines on Testicular Cancer
Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.019 · Cited by 314
Self-citation
Metadata
- Authors
- Kollmannsberger, C., Beyer, J., Droz, J. P., Harstrick, A., Hartmann, J. T., Biron, P., Fléchon, A., Schöffski, P., Kuczyk, M., Schmoll, H. J., Kanz, L., & Bokemeyer, C.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-10
- Volume
- 16
- Issue
- 10
- Pages
- 3386-3391
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1833467461
- Cited by
- 201
- References
- 0
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. https://app.cochat.ai/papers/10.1200/jco.1998.16.10.3386
- The paper
- Kollmannsberger, C., Beyer, J., Droz, J. P., Harstrick, A., Hartmann, J. T., Biron, P., Fléchon, A., Schöffski, P., Kuczyk, M., Schmoll, H. J., Kanz, L., & Bokemeyer, C. (1998). Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.10.3386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.